Page 251 - எங்களுக்கு தேசிய நிறுவனம் ஆஃப் ஒவ்வாமை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

3:12 AM MYT WASHINGTON, Dec. 28 (Xinhua) The Phase 3 trial of another investigational COVID-19 vaccine has begun enrolling adult volunteers, the U.S. National Institutes of Health (NIH) announced on Monday. The randomized, placebo-controlled trial will enroll approximately 30,000 people at approximately 115 sites in the United States and Mexico. It will evaluate the safety and efficacy of NVX-CoV2373, a vaccine candidate developed by biotechnology company Novavax, Inc. Volunteers will be asked to give informed consent prior to their participation in the trial. They will be grouped into two cohorts: individuals 18 through 64 years old and those aged 65 and older, with a goal of enrolling at least 25 percent of all volunteers who are 65 years old or older.

United statesUs biomedical advanced researchUs national institutes of healthDevelopment authorityNovavax incUs national institute of allergyInfectious diseasesAdvanced researchஒன்றுபட்டது மாநிலங்களில்எங்களுக்கு தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம்வளர்ச்சி அதிகாரம்எங்களுக்கு தேசிய நிறுவனம் ஆஃப் ஒவ்வாமைதொற்று நோய்கள்